A clinical trial for patients with Ankylosing Spondylitis (AS) or non-radiographic Axial Spondyloarthritis (nr-axSpA), to receive study treatment using an intravenous (IV) form of secukinumab, instead of a subcutaneous injectable.
Why should I participate in this clinical trial?
If living with AS or nr-axSpA is causing you constant pain and disrupting your life, even with current treatment, this trial may be the first step towards helping find a treatment for the long-term relief you deserve.
If you or someone you care about is living with AS or nr-axSpA, Novartis invites you to take part in a new clinical trial for an IV form of secukinumab. To potentially help patients get faster and longer-lasting relief from this condition, we are looking for people who have been diagnosed with AS or nr-axSpA to participate in the development and delivery of this new medicine. We are seeking 500 participants globally, 90 in the United States.
We are working to develop an IV version of the medicine that might:
- Make treatment easier and more effective for patients with weight issues and co-occurring conditions
- Offer faster relief from inflammatory pain and symptoms through direct IV administration
- Provide an alternative for patients that don't like needles, and patients with advanced disease that struggle to inject themselves